Ritmonorm (propafenone hydrochloride) coated tablets 150 mg. №50

Description

Ritmonorm (propafenone hydrochloride) coated tablets 150 mg. №50

Composition

active substance: propafenone hydrochloride;

1 tablet contains propafenone hydrochloride 150 mg;

auxiliary substances: microcrystalline cellulose, croscarmellose sodium, corn starch, hypromellose, magnesium stearate, purified water, macrogol 400, macrogol 6000, titanium dioxide (E 171).

Medicinal form

Film-coated tablets.

The main physicochemical properties: tablets covered with a film shell, from white to almost white in color, biconvex, with an embossing of “150” on one side.

Pharmacotherapeutic group

Medicines for the treatment of heart diseases. Antiarrhythmic drugs of the IS class. Propafenone.
ATX code C01B C03.

Pharmacological properties

Propafenone is an antiarrhythmic agent of the IS class.

It has a stabilizing effect on myocardial membranes, reduces the fast inward current conducted by sodium ions, with a decrease in the speed of depolarization, and prolongs the conduction time of the impulse through the atrium, the AV node, and mainly through the His–Purkinje conduction system.

Impulse conduction along additional pathways, as in WPW syndrome (Wolf–Parkinson–White syndrome), is inhibited due to prolongation of the refractory period or blockade of the conduction pathway in both anterograde and predominantly retrograde directions.

At the same time, spontaneous excitability decreases due to an increase in the threshold of myocardial sensitivity, while electrical excitability of the myocardium decreases due to an increase in the threshold of ventricular fibrillation.

Antiarrhythmic effects: slowing down the growth rate of the action potential, reducing excitability, homogenizing the conductivity coefficient, suppressing ectopic automatism, reducing the tendency of the myocardium to fibrillation.

Indications

Ritmonorm is a drug from the group of IC class antiarrhythmic drugs. It is prescribed for the treatment and prevention of ventricular arrhythmias, as well as paroxysmal supraventricular tachyarrhythmias, including paroxysmal atrial fibrillation / flutter, paroxysmal circular tachycardias with the inclusion of the atrioventricular node or auxiliary pathways. Propafenone has the property of exerting a stabilizing effect on the myocardial septum.

When treating with Ritmonorm, the patient has a decrease in spontaneous excitability, due to an increase in the sensitivity threshold of the myocardium. At the same time, the myocardium decreases electroexcitability due to an increase in the threshold of ventricular fibrillation.

Contraindications

Do not prescribe to patients who are allergic to porpafenone or other additional substances, as part of Rimonorm, or to those taking ritonavir.
Also, one should not resort to treatment with Ritmonorm for Brugada syndrome, organic heart disease, cardiogenic shock, bradycardia, sinus node disorder, atrioventricular block, atrial conduction disorder, distal blockade and blockade of the His bundle. Also, the drug is contraindicated in patients with impaired water and electrolyte balance, low blood pressure, and severe lung disease.
Use with caution for the treatment of patients with violations of the hepatobiliary system, liver, kidneys, heart failure, as well as patients with built-in pacemakers.

Application during pregnancy and lactation

There is no data that would indicate the complete safety of the use of Hexasprey for women during the period of bearing a child, because clinical trials of the drug on pregnant women are not carried out. Lactation during treatment with Ritmonorm should be canceled.

Method of administration and dosage

They start taking Ritmonorm exclusively in a hospital, orally, after eating, drinking water. The dosage is selected individually, after monitoring the heart rate, blood pressure, electrocardiogram.
The starting dose is 150 mg 3 times a day. After 3 days, it is permissible to double a single dose, but take the drug twice a day. It is allowed to increase it to three times a day, three times a day, up to the maximum allowable 900 mg per day.
If the patient weighs up to 70 kg, the dose should be reduced for patients suffering from disorders of the hepatobiliary system, kidneys, and elderly patients.
The effect of taking Ritmonorm increases when taken with anesthetics and drugs that can inhibit myocardial function.

Overdose

An overdose of Ritmonorm can lead to death. Undesirable changes in the work of the myocardium may occur, pressure may drop. Overdose symptoms may also be drowsiness, convulsions. Dialysis is ineffective. Treatment for overdose should focus on maintaining heart muscle function. Symptomatic treatment is also prescribed.

Side effects

Reception of Ritmonorm causes various side effects. Probably the development of agranulocytosis, thrombocytopenia, purpura, anemia, leukopenia, hematomas, granulocytopenia, may increase the bleeding time. Disturbances from the central nervous system (disturbances of sleep, speech, vision) are widespread; cardiovascular system (various disorders of the heart, from tachycardia to heart failure); from the gastrointestinal tract (epigastric pain, gastroenteritis); liver function (jaundice, cholestasis, hepatitis); kidney (nephrosis, failure).
It is also possible to develop erectile dysfunction, arthralgia, allergic skin reactions.